HERON THERAPEUTICS, INC. /DE/ - Common Stock, par value $0.01 per share (HRTX)

Historical Holders from Q1 2014 to Q3 2025

Symbol
HRTX on Nasdaq
CUSIP
427746102
Type / Class
Equity / Common Stock, par value $0.01 per share
Shares outstanding
183M
All holders as of September 30, 2025
Q3 2025
Total 13F shares, excl. options
153M
Holdings value
$192M
% of all portfolios
0.003%
Grand Portfolio weight change
+0%
Number of holders
169
Number of buys
71
Number of sells
-68
Average Value change %
+0%
Average buys %
+0.001%
Average sells %
0%
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of HERON THERAPEUTICS, INC. /DE/ - Common Stock, par value $0.01 per share (HRTX)

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
Rubric Capital Management LP 15.9% -8.89% $37.9M $1.19M 30M +3.25% Rubric Capital Management LP Oct 15, 2025
Clearline Capital LP 5.3% $11.7M 9.71M Clearline Capital LP Sep 30, 2025
VANGUARD GROUP INC 4.61% $10.7M 8.46M The Vanguard Group Sep 30, 2025

Institutional Holders of HERON THERAPEUTICS, INC. /DE/ - Common Stock, par value $0.01 per share (HRTX)

Period Reported Shares, Excl. Options Value, Excl. Options Change Price Investors
2025 Q3 153M $192M +$22.5M $1.26 169
2025 Q2 131M $272M +$13M $2.07 170
2025 Q1 125M $274M +$22M $2.20 164
2024 Q4 115M $176M -$13.1M $1.53 161
2024 Q3 122M $242M -$29.2M $1.99 169
2024 Q2 130M $454M +$35.4M $3.50 190
2024 Q1 119M $330M +$20.4M $2.77 157
2023 Q4 41.4K $70.3K $1.70 1
2023 Q3 118M $122M +$20M $1.03 138
2023 Q2 98.6M $114M -$11.7M $1.16 142
2023 Q1 101M $152M -$16.2M $1.51 151
2022 Q4 116M $289M -$30.9M $2.50 173
2022 Q3 118M $499M +$44.2M $4.22 173
2022 Q2 112M $313M +$4.2M $2.79 156
2022 Q1 108M $620M -$95.4M $5.72 172
2021 Q4 117M $1.07B +$79.7M $9.13 187
2021 Q3 107M $1.15B +$45.4M $10.69 192
2021 Q2 103M $1.6B +$204M $15.52 185
2021 Q1 90.5M $1.47B -$13.8M $16.21 187
2020 Q4 90.3M $1.91B +$27.9M $21.16 176
2020 Q3 90.8M $1.35B +$33M $14.82 172
2020 Q2 85.6M $1.29B -$48.8M $14.71 179
2020 Q1 92M $1.08B -$128M $11.74 179
2019 Q4 98.5M $2.31B +$190M $23.50 190
2019 Q3 85.8M $1.59B -$40M $18.50 170
2019 Q2 93.8M $1.74B +$14.3M $18.59 168
2019 Q1 86.5M $2.11B +$26.5M $24.44 185
2018 Q4 85.3M $2.21B +$96.8M $25.94 165
2018 Q3 81.5M $2.58B +$144M $31.65 186
2018 Q2 76.4M $2.96B +$199M $38.85 189
2018 Q1 72.5M $2B +$345M $27.60 148
2017 Q4 60.5M $1.09B +$99.7M $18.10 120
2017 Q3 63.3M $1.02B -$89.8M $16.15 100
2017 Q2 60.7M $841M +$47.5M $13.85 99
2017 Q1 62.4M $936M +$300M $15.00 93
2016 Q4 52.6M $689M +$4.71M $13.10 91
2016 Q3 44.9M $774M +$71.9M $17.23 86
2016 Q2 47M $848M +$17.2M $18.05 89
2016 Q1 39.8M $756M -$8.62M $18.99 97
2015 Q4 45.4M $1.21B +$41.6M $26.70 102
2015 Q3 43.7M $1.06B +$172M $24.40 100
2015 Q2 35.8M $1.12B +$319M $31.16 83
2015 Q1 26.3M $383M +$30.8M $14.55 64
2014 Q4 24.6M $247M +$2.54M $10.06 62
2014 Q3 24.2M $202M -$7.8M $8.33 54
2014 Q2 26.5M $326M +$63.3M $12.32 65
2014 Q1 16.4M $228M +$222M $13.91 38